A large and increasing fraction of orally administered small molecules in pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate. To address this trend, evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Amorphous solid dispersions (ASDs) are a prevalent technology for addressing oral bioavailability challenges, given the applicability and scalability of the technology across a diverse compound property space.

Developing ASDs requires an integrated approach, where bioperformance, physical and chemical stability as well as manufacturability are all considered. This webinar covers some general strategies for developing a successful amorphous solid dispersion formulation, from formulation intermediates to final dosage forms. Aspects of formulation screening, stability and manufacture will be covered including strategies for incorporating ASDs into immediate release tablets.

A case study demonstrating successful formulation of ASDs into a novel dosage form architecture will be presented.

In this webinar you’ll learn:

• Formulation screening strategies for amorphous solid dispersions

• Details on an integrated approach for developing ASDs including performance, stability and manufacture

• Strategy for incorporating ASDs into dosage forms, including a novel dosage form architecture for ASDs

Who should attend:

• Large pharma, mid-size pharma, biotech companies, consultants

• Technical positions involved in process development and scale-up, early- to late- stage development, or commercialization

• Senior managers, scientists, engineers, R&D managers